A phase 2 study to evaluate the safety, tolerability, and activity of fontolizumab in subjects with active rheumatoid arthritis

Trial Profile

A phase 2 study to evaluate the safety, tolerability, and activity of fontolizumab in subjects with active rheumatoid arthritis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2006

At a glance

  • Drugs Fontolizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors PDL BioPharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Aug 2006 Status change
    • 27 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top